112 related articles for article (PubMed ID: 7524219)
21. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine.
Lemahieu WP; Maes BD; Vanrenterghem Y
Transplant Proc; 2005 Jun; 37(5):2051-3. PubMed ID: 15964336
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine.
Jiang H; Fujitsu T; Sakuma S; Ogawa T; Tamura K; Fujii Y; Akiyama Y; Izumi S; Takahara S; Ishibashi M
Transplant Proc; 1995 Feb; 27(1):367-9. PubMed ID: 7533413
[No Abstract] [Full Text] [Related]
23. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination.
Ferraresso M; Ghio L; Tirelli S; Pedotti P; Taioli E; Edefonti A; Berardinelli L
Transplant Proc; 2004 Apr; 36(3):685-6. PubMed ID: 15110630
[TBL] [Abstract][Full Text] [Related]
24. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group.
Ochiai T; Fukao K; Takahashi K; Endo T; Oshima S; Uchida K; Yokoyama I; Ishibashi M; Takahara S; Iwasaki Y
Transplant Proc; 1995 Feb; 27(1):829-33. PubMed ID: 7533435
[No Abstract] [Full Text] [Related]
25. Do early cyclosporine levels affect the incidence of acute rejection in renal transplant recipients?
Johnson EM; Canafax DM; Gillingham K; Schmidt W; Pandian K; Najarian JS; Matas AJ
Transplant Proc; 1996 Apr; 28(2):879. PubMed ID: 8623444
[No Abstract] [Full Text] [Related]
26. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients.
Dudley CR;
Transplant Proc; 2001; 33(1-2):1034-5. PubMed ID: 11267179
[No Abstract] [Full Text] [Related]
27. Advantage--FK 506: reduced chronic rejection for lung transplant recipients.
Bolman RM
Ann Thorac Surg; 1995 Sep; 60(3):495-6. PubMed ID: 7545888
[No Abstract] [Full Text] [Related]
28. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
[TBL] [Abstract][Full Text] [Related]
29. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese D
Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
[No Abstract] [Full Text] [Related]
30. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression.
Sugito K; Morozumi K; Oikawa T
Transplant Proc; 1996 Jun; 28(3):1335-7. PubMed ID: 8658683
[No Abstract] [Full Text] [Related]
32. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients.
Shinozuka N; Koyama I; Omoto R; Burdick J
Transplant Proc; 1996 Jun; 28(3):1259. PubMed ID: 8658649
[No Abstract] [Full Text] [Related]
33. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up.
Offner G; Burdelski M; Hoyer PF; Winkler M; Brodehl J
Transplant Proc; 1991 Dec; 23(6):3082-4. PubMed ID: 1721366
[No Abstract] [Full Text] [Related]
34. Clinical experience in transferring kidney transplant patients from sandimmun to sandimmun neoral--results after 6 months.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
Transplant Proc; 1995 Oct; 27(5):2679-82. PubMed ID: 7482873
[No Abstract] [Full Text] [Related]
35. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients.
Maes BD; Lemahieu W; Kuypers D; Evenepoel P; Coosemans W; Pirenne J; Vanrenterghem YF
Am J Transplant; 2002 Nov; 2(10):989-92. PubMed ID: 12484345
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up.
Montagnino G; Krämer BK; Arias M;
Transplant Proc; 2002 Aug; 34(5):1635-7. PubMed ID: 12176515
[No Abstract] [Full Text] [Related]
37. FK 506 conversion of renal allografts failing cyclosporine immunosuppression.
Jordan ML; Shapiro R; Jensen CW; Scantlebury V; Fung J; Tzakis A; McCauley J; Jain A; Demetrius J; Randhawa P
Transplant Proc; 1991 Dec; 23(6):3078-81. PubMed ID: 1721365
[No Abstract] [Full Text] [Related]
38. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases.
Morris-Stiff G; Singh J; Ostrowski K; Balaji V; Moore R; Darby C; Lord R; Jurewicz WA
Transplant Proc; 1998 Jun; 30(4):1295-6. PubMed ID: 9636525
[No Abstract] [Full Text] [Related]
39. Tacrolimus (FK 506) in kidney transplantation.
Vanrenterghem Y
Transplant Proc; 1998 Aug; 30(5):2171-3. PubMed ID: 9723431
[No Abstract] [Full Text] [Related]
40. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
Laskow DA; Vincenti F; Neylan JF; Mendez R; Matas AJ
Transplantation; 1996 Oct; 62(7):900-5. PubMed ID: 8878381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
